Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TIKOSYN vs CARNEXIV
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective class III antiarrhythmic agent; blocks cardiac potassium channels (IKr), prolonging action potential duration and effective refractory period.
CARNEXIV is a formulation of carbidopa and levodopa; levodopa is converted to dopamine in the brain, replenishing depleted dopamine in the striatum, while carbidopa inhibits peripheral decarboxylation of levodopa, increasing central availability.
Conversion of atrial fibrillation/atrial flutter to normal sinus rhythm,Maintenance of normal sinus rhythm in patients with symptomatic atrial fibrillation/atrial flutter
Treatment of Parkinson's disease,Post-encephalitic parkinsonism,Symptomatic parkinsonism following carbon monoxide or manganese intoxication
500 mcg orally twice daily for atrial fibrillation/flutter conversion and maintenance of sinus rhythm.
1 mg intravenously once daily for 7 days, followed by 1 mg orally once daily for 7 days.
10 hours (terminal) in patients with normal renal function; prolonged to up to 42 hours in severe renal impairment; clinically relevant for dosing interval adjustment.
Terminal elimination half-life is 8-12 hours in patients with normal renal function; prolonged in renal impairment (up to 24-36 hours with Cr Cl <30 m L/min)
Primarily metabolized by CYP3A4; also undergoes N-dealkylation and glucuronidation; renal excretion of unchanged drug (20-30%) and metabolites.
Levodopa is metabolized by aromatic L-amino acid decarboxylase (AAAD) and catechol-O-methyltransferase (COMT) peripherally and centrally; carbidopa is metabolized mainly via renal excretion and some hepatic metabolism.
Renal: 80% as unchanged drug; biliary/fecal: 20% (metabolites and minor parent drug).
Renal (approximately 70% as unchanged drug and metabolites), biliary/fecal (approximately 25-30%)
96% bound to plasma proteins (primarily albumin).
Approximately 85-90%, primarily to albumin and alpha-1-acid glycoprotein
3 L/kg (range 2-4 L/kg), indicating extensive tissue distribution, particularly to cardiac tissue.
0.8-1.2 L/kg, indicating extensive extravascular distribution
>90% after oral administration (approximately 93% with low first-pass metabolism).
Oral: 50-70% (first-pass metabolism); Intravenous: 100%
Cr Cl > 60 m L/min: 500 mcg BID. Cr Cl 40-60 m L/min: 250 mcg BID. Cr Cl < 40 m L/min: contraindicated.
GFR 30-89 m L/min: no adjustment; GFR 15-29 m L/min: reduce dose to 0.5 mg IV once daily for 7 days then 0.5 mg PO once daily for 7 days; GFR <15 m L/min or dialysis: not recommended.
No formal Child-Pugh based adjustment; use caution in severe hepatic impairment due to limited data.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose to 0.5 mg IV once daily for 7 days then 0.5 mg PO once daily for 7 days; Child-Pugh C: not recommended.
Safety and efficacy not established in pediatric patients.
Not approved for pediatric use; safety and efficacy not established.
Adjust based on renal function per Cr Cl; monitor QTc interval closely due to increased risk of toxicity.
No specific dose adjustment; use caution due to potential increased sensitivity and renal impairment.
Tikosyn can cause life-threatening ventricular arrhythmias (e.g., torsade de pointes) and must be initiated in a hospital setting with continuous ECG monitoring and dose adjustment based on creatinine clearance and QTc interval.
None.
QTc prolongation; hypokalemia; hypomagnesemia; renal impairment; bradycardia; concurrent use of other QT-prolonging drugs; drug interactions with CYP3A4 inhibitors.
May cause falling asleep during activities of daily living,May cause dyskinesias or exacerbate pre-existing dyskinesia,May cause hallucinations and psychosis,May cause hypotension, especially orthostatic hypotension,May cause impulse control disorders,May cause withdrawal-emergent hyperpyrexia and confusion upon abrupt discontinuation,May cause melanoma risk (monitor skin lesions),May cause gastrointestinal bleeding in patients with history of peptic ulcer,May cause neuroleptic malignant syndrome-like reaction on rapid dose reduction
Baseline QTc > 440 msec (500 msec in ventricular conduction abnormalities); severe renal impairment (Cr Cl < 20 m L/min); concurrent use of verapamil, cimetidine, ketoconazole, trimethoprim, or other drugs that prolong QT; congenital long QT syndrome; history of torsade de pointes; hypersensitivity to dofetilide.
Concurrent use of nonselective MAO inhibitors (e.g., MAO-A or MAO-B) due to risk of hypertensive crisis,History of malignant melanoma or undiagnosed skin lesions,Narrow-angle glaucoma,Known hypersensitivity to carbidopa or levodopa
Grapefruit juice inhibits CYP3A4, increasing dofetilide levels and risk of arrhythmia; avoid grapefruit and grapefruit juice. High-potassium foods (e.g., bananas, oranges, spinach) are generally safe but must be consumed consistently to avoid electrolyte fluctuations. Avoid excessive licorice intake which can cause hypokalemia.
No known food interactions. Take with food if gastrointestinal upset occurs. Avoid alcohol as it may increase risk of adverse effects.
Pregnancy Category C. Animal studies have shown fetal toxicity (increased fetal loss, reduced fetal weight) at maternally toxic doses. No adequate and well-controlled studies in pregnant women. Potential fetal risks in all trimesters; use only if benefit justifies risk.
CARNEXIV (valbenazine) is classified as Pregnancy Category C. No adequate and well-controlled studies in pregnant women. In animal studies, fetal developmental toxicity (including reduced fetal body weight and increased skeletal variations) was observed at maternal toxic doses. Use during pregnancy only if potential benefit justifies potential risk to the fetus. First trimester: theoretical risk based on mechanism (VMAT2 inhibition); second and third trimesters: unknown risk; limited human data.
Not recommended. It is unknown if TIKOSYN is excreted in human milk. M/P ratio not available. Potential for serious adverse reactions in nursing infants; discontinue nursing or drug.
It is unknown if valbenazine or its metabolites are excreted in human breast milk; however, valbenazine is excreted in rat milk. Because of the potential for serious adverse reactions in nursing infants, advise patients that breastfeeding is not recommended during treatment. M/P ratio not available in humans.
Dosing adjustments not specifically defined for pregnancy. Use standard dosing based on renal function and QTc interval. However, due to potential pharmacokinetic changes in pregnancy (increased volume of distribution, altered clearance), monitor drug levels (if available) and adjust dose cautiously, targeting therapeutic QTc effect.
No specific dosing adjustments are recommended due to lack of pharmacokinetic data in pregnancy. However, physiological changes in pregnancy (increased plasma volume, renal clearance, hepatic metabolism) may alter valbenazine exposure. Monitor clinical response and tolerability; adjust dose as needed.
TIKOSYN (dofetilide) is a class III antiarrhythmic indicated for maintenance of sinus rhythm in patients with atrial fibrillation/flutter. Requires inpatient initiation with continuous ECG monitoring due to risk of torsade de pointes. Dosing is based on creatinine clearance and QTc interval; must not exceed 500 mcg twice daily. Drug interactions via CYP3A4 and renal clearance are critical; avoid verapamil, cimetidine, ketoconazole, and trimethoprim. Hypokalemia and hypomagnesemia must be corrected before use.
CARNEXIV (intravenous carnitine) is indicated for primary and secondary carnitine deficiency in patients undergoing hemodialysis. Monitor for seizures, especially in patients with pre-existing seizure disorders. Do not administer in patients with hypersensitivity to carnitine. Adjust dose in hepatic impairment. Use with caution in renal impairment; monitor serum carnitine levels. Infusion rate should not exceed 500 mg/min to minimize adverse effects.
You must be hospitalized for the first 3 days of treatment to monitor your heart rhythm.,Do not take any new medications, including over-the-counter drugs or herbal supplements, without consulting your doctor.,Report any fainting, lightheadedness, or palpitations immediately.,Take your dose exactly as prescribed, usually twice daily with or without food.,Do not skip doses or double up if you miss a dose; call your doctor if you miss more than one dose.,Avoid grapefruit juice and grapefruit products while on this medication.,Your kidney function will be checked regularly; keep all lab appointments.,Inform all healthcare providers that you are taking TIKOSYN.
This medication is used to treat carnitine deficiency, often due to long-term kidney dialysis.,You may experience nausea, vomiting, or diarrhea; report severe symptoms to your doctor.,Seek immediate medical help if you have seizures or signs of an allergic reaction (rash, itching, swelling, severe dizziness, trouble breathing).,Do not stop this medication suddenly without consulting your healthcare provider.,Keep all appointments for blood tests to monitor carnitine levels.,Inform your doctor about all other medicines you take, including over-the-counter drugs and supplements.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TIKOSYN vs CARNEXIV, answered by our medical review team.
TIKOSYN is a Antiarrhythmic Agent that works by Selective class III antiarrhythmic agent; blocks cardiac potassium channels (IKr), prolonging action potential duration and effective refractory period.. CARNEXIV is a Antiarrhythmic Agent that works by CARNEXIV is a formulation of carbidopa and levodopa; levodopa is converted to dopamine in the brain, replenishing depleted dopamine in the striatum, while carbidopa inhibits peripheral decarboxylation of levodopa, increasing central availability.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TIKOSYN and CARNEXIV depend on the specific clinical indication. These are both Antiarrhythmic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TIKOSYN is: 500 mcg orally twice daily for atrial fibrillation/flutter conversion and maintenance of sinus rhythm.. The standard adult dose of CARNEXIV is: 1 mg intravenously once daily for 7 days, followed by 1 mg orally once daily for 7 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TIKOSYN and CARNEXIV in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TIKOSYN is classified as Category C. Pregnancy Category C. Animal studies have shown fetal toxicity (increased fetal loss, reduced fetal weight) at maternally toxic doses. No adequate and well-controlled studies in pr. CARNEXIV is classified as Category C. CARNEXIV (valbenazine) is classified as Pregnancy Category C. No adequate and well-controlled studies in pregnant women. In animal studies, fetal developmental toxicity (including . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.